Shukra Pharmaceuticals Ltd. has received a Letter of Intent from the Yamuna Expressway Industrial Development Authority (YEIDA) for the allotment of 10 acres of land in the Medical Device Park at Greater Noida. The company plans to invest around Rs 600 crore to establish a manufacturing facility focused on advanced surgical robotics and Boron Neutron Capture Therapy (BNCT), a next-generation treatment designed for complex cancer cases.
The upcoming facility is expected to create more than 900 direct jobs and nearly 2,000 indirect employment opportunities, reinforcing India’s position as a growing hub for healthcare innovation.
In a parallel development, Shukra Pharmaceuticals has signed a Memorandum of Understanding (MoU) with Borns Medical Robotics Inc. to introduce advanced surgical robotics technology in India. The agreement, formalised at an event in New Delhi, will bring the Veer Surgical Robot, an AI-powered surgical platform designed to improve precision, safety, and patient outcomes, while expanding access to advanced healthcare technologies across the country.
Dr Minakshi Late, CEO and Global Head of Shukra Ltd., said the collaboration aligns with India’s Atmanirbhar Bharat vision. She emphasised that the initiative aims to make advanced surgical technologies more affordable and accessible, particularly for patients in underserved regions.
Dr Alexander T. Teichmann, Chief Medical Officer at Borns Medical Robotics Inc., highlighted that the partnership combines Borns’ AI-driven robotic capabilities with Shukra’s market presence. He noted that the collaboration aims to enhance surgical efficiency, standardise clinical outcomes, and develop scalable healthcare infrastructure across India and Asia.
Dakshesh Shah, Chairman and Managing Director of Shukra Pharmaceuticals Ltd., stated that the company is committed to ensuring wider access to world-class healthcare technologies at affordable prices. He added that the collaboration marks a significant step toward expanding robotic surgical care beyond metropolitan and premium healthcare facilities.
Dr Vivek Bindal, Director and Head of the Max Institute of Robotic Surgery, Patparganj, who participated in early trials of the technology, said the introduction of next-generation robotic platforms like Veer could significantly transform surgical care. He noted that features such as single-port surgery, AI-based safety systems, and advanced micro-instruments are expected to improve surgical precision, reduce invasiveness, and expand access to high-quality surgical procedures across India.
